Pharmaceutical intermediates

Pharmaceutical intermediates are chemical compounds that create the structure segments of the active pharmaceutical ingredient (API).

Pharmaceutical intermediates

Bis(4-nitrophenyl)sulfane

Pharmaceutical intermediates

Ethyl 6-(4-iodophenyl)-1-(4-methoxy phenyl)-7- oxo-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4- c]pyridine-3-carboxylate

Pharmaceutical intermediates

Ethyl 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro1H-pyrazolo[3,4-c]pyridine-3-carboxylate

Pharmaceutical intermediates

3, 3-dichloro-1-(4-iodophenyl) piperidin-2-one

Pharmaceutical intermediates

1-(2,3-Dichlorophenyl) Piperazine HCl

Pharmaceutical intermediates

1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-,2,3,4,6-tetraacetate, (1S)- D-Glucitol

Pharmaceutical intermediates

5-Bromo-2-chloro4’ethoxydiphenylmethane

Pharmaceutical intermediates

N-Benzhydrylpiperazine

Pharmaceutical intermediates

(10S)-10,11-Dihydro-10-hydroxy-5Hdibenz[b,f]azepine-5-carboxamide

Pharmaceutical intermediates

Carbamic acid, N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-nitrophenyl)sulfonyl]amino]-1- (phenylmethyl)propyl]-,1,1-dimethylethylester

Pharmaceutical intermediates

2,3,4,6-tetra-O-trimethylsilyl-ß-D-glucolactone

Pharmaceutical intermediates

4,4′-sulfonylbis(nitrobenzene)

Pharmaceutical intermediates

2-Bromo-4′-benzyloxy-3′-nitroacetophenone

Pharmaceutical intermediates

(1E)-N-Hydroxy-5-Methoxy-1-(4-Trifluoromethylphenyl)Pentan-1-Imine

Pharmaceutical intermediates

4,4′-Difluorobenzhydrylpiperazine

Pharmaceutical intermediates

10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide

Pharmaceutical intermediates

5-methylpyridin-2(1H)-one/2-Hydroxy-5- methylpyridine

Pharmaceutical intermediates

(1R)-2-{[2-(4-nitrophenyl)ethyl]amino}-1-phenylethanol

Pharmaceutical intermediates

2,4-Dihydro-4-[4-[4-(4-methoxyphenyl)-1- piperazinyl]phenyl]-2-(1-methyl propyl)-3H-1,2,4-triazol-3-one

Pharmaceutical intermediates

1-Acetyl-4-(4-hydroxyphenyl) piperazine

Pharmaceutical intermediates

2-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5-yl}methyl)-1H-isoindole-1,3(2H)-dione

Pharmaceutical intermediates

4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one hydrochloride

Pharmaceutical intermediates

Pharmaceutical intermediates

Dibenzo [b, f] [1, 4] thiazepin- 11(10H)-one

Pharmaceutical intermediates

1-Acetamido 3,5-dimethyl Adamantane*

Pharmaceutical intermediates

2-(((3aR,4S,6R,6aS)-6-((5-amino-6-chlo ro-2-(propylthio)pyrimidin-4-yl)amino) -2,2-dimethyltetrahydro-3aH-cyclo penta[d][1,3]dioxol-4-yl)oxy)ethanol

Search

After entering the query, click on the search result

Ikigai Corporation Company is a leading pharmaceutical contract development and manufacturing organisation (CDMO) for both APIs and finished dose forms.

Copyright © 2022 IKIGAI CORPORATION. All rights reserved.